Risk-adapted surveillance
Risk-adapted surveillance has been studied in 3 papers since 2026: none in people yet, 3 reviews; 3 in the past year. No study of it in people or animals has been published yet. The newest paper, Nov 2, 2026: “Second Primary Malignancies After CAR T-Cell Therapy: Causal Attribution, Clonal Evolution, and Risk-Adapted Surveillance”.
3 papers study it1 findingUpdated
2 new papers in 30 daysSee all 3
What did studies of Risk-adapted surveillance find?
1Studies of Risk-adapted surveillance measured 1 outcome; the most studied are colorectal cancer (1 study).
Colorectal cancer
downin reviews1
1 study
Colorectal cancer
downin reviews1
Risk-adapted surveillance prevents colorectal cancer.
“A phase-based approach combining cumulative diagnosis, effective clearance, risk-adapted 1- or 2-year surveillance, selective surgery, and screening of first-degree relatives provides a pragmatic framework for CRC prevention.”
Reviewas part of a phase-based approach with effective clearance, selective surgery and family screening
International journal of general medicine
Latest
3 papers in 12 monthsFrontiers in Immunology
Second Primary Malignancies After CAR T-Cell Therapy: Causal Attribution, Clonal Evolution, and Risk-Adapted Surveillance
Accepted, not yet published: reviewBlood and immune system
International Journal of General Medicine
Serrated Polyposis Syndrome: A Narrative Review from Clinical Recognition to Risk-Adapted Cancer Prevention
ReviewInterventions